Product has been added to your cart.

Disease Modeling

Axol has over 60 different patient disease lines in stock. If you want to reliably model diseases like Alzheimer’s, Parkinson’s or ALS using human iPSC-derived cells in a dish, browse our catalog to see which lines have the genetic backgrounds and Isogenic controls to suit your needs. We provide fully defined differentiated cells from these disease lines.

iPSC Research Spotlight

Scientists around the world are using iPSCs for innovative research

Selina Wray, Alzheimer’s Research UK

We spoke with Selina Wray, Professor of Molecular Neuroscience and Alzheimer’s Research UK Senior Research Fellow in the Department of Neurodegenerative Disease at UCL Queen Square Institute of Neurology, London.

Selina explained how developing in vitro models of Alzheimer’s Disease using iPSC’s derived from patient cells will improve translation of therapies to the clinic for the treatment of this neurodegenerative disease.

Human iPSC-derived disease lines from patient donors

Alzheimer’s Disease CENSOi077-C

CENSOi077-A

PBMCs (52 Yr Female)

ApoE

Alzheimer’s Disease CENSOi074-A

CENSOi074-A

PBMCs (60 Yr Male)

ApoE

Alzheimer’s Disease CENSOi070-A

CENSOi070-A

PBMCs (59 Yr Female)

ApoE

axoCells

Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (APOE4 HOM)

ax0111

Fibroblasts (87 Yr Female)

1.5 million cells

axoCells

Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 L286V)

ax0112

Fibroblasts (38 Yr Female)

1.5 million cells

axoCells

Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 M146L)

ax0113

Fibroblasts (53 Yr Male)

1.5 million cells

axoCells

Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 A246E)

ax0114

Fibroblasts (31 Yr Female)

1.5 million cells

Frontotemporal Dementia, ALS CENSOi018-A

CENSOi018-A

Fibroblasts (62 Yr Female)

TDP43

Amyotrophic Lateral Sclerosis (ALS) (unaffected) CENSOi027-D

CENSOi027-D

Fibroblasts (44 Yr Female)

C9ORF72

Amyotrophic Lateral Sclerosis (ALS) CENSOi035-B

CENSOi035-B

Fibroblasts (61 Yr Female)

SOD1

Charcot-Marie Tooth Disease Patient 27 Yr Male

Charcot-Marie-Tooth Disease, Type 4J (CMT4J) CENSOi068-A

CENSOi068-A

PBMCs (27 Yr Male)

FIG4

Dentatorubral-Pallidoluysian Atrophy (DRPLA) CENSOi058-A

CENSOi058-A

Fibroblasts (45 Yr Female)

ATN1

Dentatorubral-Pallidoluysian Atrophy (DRPLA) CENSOi055-A

CENSOi055-A

Fibroblasts (51 Yr Male)

ATN1

Dentatorubral-Pallidoluysian Atrophy (DRPLA) CENSOi054-B

CENSOi054-Ba

Fibroblasts (16 Yr Male)

ATN1

Dentatorubral-Pallidoluysian Atrophy (DRPLA) CENSOi054-B

CENSOi054-B

Fibroblasts (16 Yr Male)

ATN1

Friedreich’s Ataxia (familial control) CENSOi038-A

CENSOi038-A

Fibroblasts (Unknown Yr Female)

FXN

Friedreich’s Ataxia (control) CENSOi039-A

CENSOi039-A

Fibroblasts (44 Yr Male)

FXN

Friedreich’s Ataxia CENSOi050-A

CENSOi050-A

Fibroblasts (34 Yr Male)

FXN

Friedreich’s Ataxia CENSOi048-A

CENSOi048-A

Fibroblasts (23 Yr Male)

FXN

Friedreich’s Ataxia CENSOi044-A

CENSOi044-A

Fibroblasts (17 Yr Female)

FXN

Friedreich’s Ataxia CENSOi037-A

CENSOi037-A

Fibroblasts (21 Yr Male)

FXN

Human iPSC-derived neural stem cells from healthy donors

Frontotemporal Dementia (FTD) CENSOi062-A

CENSOi062-A

Fibroblasts (46 Yr Female)

MAPT at risk

Frontotemporal Dementia (FTD) CENSOi032-A

CENSOi032-A

Fibroblasts (65 Yr Male)

Progranulin

Frontotemporal Dementia (FTD) CENSOi025-A

CENSOi025-A

Fibroblasts (31 Yr Female)

Progranulin

Frontotemporal Dementia (FTD) CENSOi069-B

CENSOi069-B

PBMCs (54 Yr Female)

MAPT

Frontotemporal Dementia, ALS CENSOi018-A

CENSOi018-A

Fibroblasts (62 Yr Female)

TDP43

Frontotemporal Dementia (FTD), Paget’s Disease CENSOi043-A

CENSOi043-A

Fibroblasts (42 Yr Male)

VCP

Frontotemporal Dementia (FTD), Paget’s Disease CENSOi042-A

CENSOi042-A

Fibroblasts (43 Yr Female)

VCP

Frontotemporal Dementia (FTD) CENSOi076-A

CENSOi076-A

PBMCs (35 Yr Male)

MAPT

Frontotemporal Dementia (FTD) CENSOi072-A

CENSOi072-A

PBMCs (42 Yr Female)

MAPT

Huntington's Disease Patient - 16 Yr Male

Huntington’s Disease CENSOi052-A

CENSOi052-A

Fibroblasts (16 Yr Male)

HTT

Huntington's Disease Patient - 40-50 Yr Female

Huntington’s Disease CENSOi011-D

CENSOi011-D

Fibroblasts (40-50 Yr Female)

HTT

Huntington’s Disease CENSOi053-A

CENSOi053-A

Fibroblasts (64 Yr Male)

HTT asymptomatic carrier

Huntington’s Disease CENSOi019-B

CENSOi019-B

Fibroblasts (7 Yr Female)

HTT

Huntington’s Disease CENSOi017-A

CENSOi017-A

Fibroblasts (51 Yr Female)

HTT

axoCells

Human iPSC-Derived Neural Stem Cells – Huntington’s Disease Patient (CAG50)

ax0211

Fibroblasts (48 Yr Female)

1.5 million cells

Mucolipidosis IV (ML4) CENSOi066-A

CENSOi066-A

PBMCs (10 Yr Male)

MCOLN1

Mucolipidosis IV (ML4) CENSOi065-B

CENSOi065-B

PBMCs (45 Yr Male)

MCOLN1

Mucolipidosis IV (ML4) CENSOi064-A

CENSOi064-A

PBMCs (10 Yr Female)

MCOLN1

Mucolipidosis IV (ML4) CENSOi063-A

CENSOi063-A

Fibroblasts (36 Yr Female)

MCOLN1

Nasu-Hakola Disease (familial control) CENSOi078-A

CENSOi078-A

PBMCs (68 Yr Male)

TREM2

Nasu-Hakola Disease CENSOi075-B

CENSOi075-B

PBMCs (69 Yr Female)

TREM2

Nasu-Hakola Disease CENSOi073-A

CENSOi073-A

PBMCs (41 Yr Female)

TREM2

Parkinsonism/Machado-Joseph disease (SCA3) CENSOi071-A

CENSOi071-A

PBMCs (22 Yr Female)

ATXN3

Parkinson’s Disease CENSOi047-A

CENSOi047-A

Fibroblasts (59 Yr Male)

LRRK2

Parkinson’s Disease CENSOi046-A

CENSOi046-A

Fibroblasts (68 Yr Male)

LRRK2

Parkinson’s Disease CENSOi045-A

CENSOi045-A

Fibroblasts (48 Yr Female)

SNCA

Parkinson's disease patient icon

Parkinson’s Disease CENSOi031-A

CENSOi031-A

Fibroblasts (54 Yr Male)

SNCA

Parkinson’s Disease CENSOi030-A

CENSOi030-A

Fibroblasts (54 Yr Female)

SNCA

Parkinson’s Disease CENSOi028-A

CENSOi028-A

Fibroblasts (52 Yr Female)

PINK1

Parkinson’s Disease CENSOi026-C

CENSOi026-C

Fibroblasts (58 Yr Male)

PINK1 & PARK2

Parkinson’s Disease CENSOi024-A

CENSOi024-A

Fibroblasts (75 Yr Male)

PINK1 & PARK2

Parkinson’s Disease CENSOi023-A

CENSOi023-A

Fibroblasts (48 Yr Female)

PINK1 & PARKIN

Spinal and Bulbar Muscular Atrophy (SBMA) CENSOi040-A

CENSOi040-A

Fibroblasts (66 Yr Male)

AR

Spinocerebellar Ataxia Type 7 (SCA7) CENSOi036-A

CENSOi036-A

Fibroblasts (61 Yr Female)

ATXN7

Spinocerebellar Ataxia Type 6 (SCA6) CENSOi056-A

CENSOi056-A

Fibroblasts (63 Yr Female)

CACNA1A

Parkinsonism/Machado-Joseph disease (SCA3) CENSOi071-A

CENSOi071-A

PBMCs (22 Yr Female)

ATXN3

Protocols & Application Notes

Enriched Cerebral Cortical Neuron Protocol

Spontaneous Neuronal Differentiation Protocol

Data – APOE Genotyping of Axol NSCs and Astrocytes

Neurotoxicology screening using a high-sensitivity MEA platform

Applications

Assay Development

Axol’s iPSC-derived cells are robust and reproducibly made, making them the perfect tool for your assay development requirements.

Co-Culture Models

Axol’s iPSC-derived cells can be grown in co-culture to provide a more physiologically relevant scenario for cellular development and function.

Cardiotoxicity Screening

Axol’s iPSC-derived cardiomyocytes are CiPA-validated, making them the perfect model for cardiotoxicity assays.

Axol Services

No results found.